Compared to single-agent formulations, EY-L exhibited superior antiproliferative effects, modulated the tumor immune microenvironment, and achieved synergistic inhibition of mTOR and survivin signaling pathways offering a compelling strategy to overcome radio resistance in RCC and potentially other malignancies [11]. This evidence concerns the gene BIRC5 and neoplasm.